126 related articles for article (PubMed ID: 12788062)
1. Serum response factor is modulated by the SUMO-1 conjugation system.
Matsuzaki K; Minami T; Tojo M; Honda Y; Uchimura Y; Saitoh H; Yasuda H; Nagahiro S; Saya H; Nakao M
Biochem Biophys Res Commun; 2003 Jun; 306(1):32-8. PubMed ID: 12788062
[TBL] [Abstract][Full Text] [Related]
2. Noncovalent SUMO-1 binding activity of thymine DNA glycosylase (TDG) is required for its SUMO-1 modification and colocalization with the promyelocytic leukemia protein.
Takahashi H; Hatakeyama S; Saitoh H; Nakayama KI
J Biol Chem; 2005 Feb; 280(7):5611-21. PubMed ID: 15569683
[TBL] [Abstract][Full Text] [Related]
3. Proteasome-independent disruption of PML oncogenic domains (PODs), but not covalent modification by SUMO-1, is required for human cytomegalovirus immediate-early protein IE1 to inhibit PML-mediated transcriptional repression.
Xu Y; Ahn JH; Cheng M; apRhys CM; Chiou CJ; Zong J; Matunis MJ; Hayward GS
J Virol; 2001 Nov; 75(22):10683-95. PubMed ID: 11602710
[TBL] [Abstract][Full Text] [Related]
4. The ND10 Component Promyelocytic Leukemia Protein Acts as an E3 Ligase for SUMOylation of the Major Immediate Early Protein IE1 of Human Cytomegalovirus.
Reuter N; Schilling EM; Scherer M; Müller R; Stamminger T
J Virol; 2017 May; 91(10):. PubMed ID: 28250117
[TBL] [Abstract][Full Text] [Related]
5. Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.
Tatemichi Y; Shibazaki M; Yasuhira S; Kasai S; Tada H; Oikawa H; Suzuki Y; Takikawa Y; Masuda T; Maesawa C
Cancer Sci; 2015 Jul; 106(7):848-56. PubMed ID: 25891951
[TBL] [Abstract][Full Text] [Related]
6. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
7. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
8. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
Adamson AL; Kenney S
J Virol; 2001 Mar; 75(5):2388-99. PubMed ID: 11160742
[TBL] [Abstract][Full Text] [Related]
9. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
11. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
[TBL] [Abstract][Full Text] [Related]
12. Sumoylation of internally initiated Sp3 isoforms regulates transcriptional repression via a Trichostatin A-insensitive mechanism.
Spengler ML; Kennett SB; Moorefield KS; Simmons SO; Brattain MG; Horowitz JM
Cell Signal; 2005 Feb; 17(2):153-66. PubMed ID: 15494207
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional activity of megakaryoblastic leukemia 1 (MKL1) is repressed by SUMO modification.
Nakagawa K; Kuzumaki N
Genes Cells; 2005 Aug; 10(8):835-50. PubMed ID: 16098147
[TBL] [Abstract][Full Text] [Related]
14. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
15. The IL-6 family of cytokines modulates STAT3 activation by desumoylation of PML through SENP1 induction.
Ohbayashi N; Kawakami S; Muromoto R; Togi S; Ikeda O; Kamitani S; Sekine Y; Honjoh T; Matsuda T
Biochem Biophys Res Commun; 2008 Jul; 371(4):823-8. PubMed ID: 18474224
[TBL] [Abstract][Full Text] [Related]
16. SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.
Duprez E; Saurin AJ; Desterro JM; Lallemand-Breitenbach V; Howe K; Boddy MN; Solomon E; de Thé H; Hay RT; Freemont PS
J Cell Sci; 1999 Feb; 112 ( Pt 3)():381-93. PubMed ID: 9885291
[TBL] [Abstract][Full Text] [Related]
17. Regulation of pokemon 1 activity by sumoylation.
Roh HE; Lee MN; Jeon BN; Choi WI; Kim YJ; Yu MY; Hur MW
Cell Physiol Biochem; 2007; 20(1-4):167-80. PubMed ID: 17595526
[TBL] [Abstract][Full Text] [Related]
18. Solubility shift and SUMOylaltion of promyelocytic leukemia (PML) protein in response to arsenic(III) and fate of the SUMOylated PML.
Hirano S; Tadano M; Kobayashi Y; Udagawa O; Kato A
Toxicol Appl Pharmacol; 2015 Sep; 287(3):191-201. PubMed ID: 26049103
[TBL] [Abstract][Full Text] [Related]
19. PML-nuclear bodies are involved in cellular serum response.
Matsuzaki K; Minami T; Tojo M; Honda Y; Saitoh N; Nagahiro S; Saya H; Nakao M
Genes Cells; 2003 Mar; 8(3):275-86. PubMed ID: 12622724
[TBL] [Abstract][Full Text] [Related]
20. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
